Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P23468
UPID:
PTPRD_HUMAN
Alternative names:
-
Alternative UPACC:
P23468; B1ALA0; F5GWT7; Q3KPJ0; Q3KPJ1; Q3KPJ2
Background:
Receptor-type tyrosine-protein phosphatase delta plays a pivotal role in neuronal development, specifically in synapse formation. It achieves this by facilitating the bidirectional induction of pre- and post-synaptic differentiation, interacting trans-synaptically with IL1RAP and IL1RAPL1, and engaging in pre-synaptic differentiation through SLITRK2.
Therapeutic significance:
Understanding the role of Receptor-type tyrosine-protein phosphatase delta could open doors to potential therapeutic strategies.